和元生物技术（上海）股份有限公司2025年半年度报告摘要

Core Viewpoint - The company is facing challenges in its cell and gene therapy CDMO business due to macroeconomic changes, industry conditions, and downstream demand, resulting in low order prices and negative gross margins, although there has been some improvement compared to the previous year [1][2]. Group 1: Company Overview - The company is focused on cell and gene therapy, which is a key development direction in the biopharmaceutical industry, supported by national and local policies [2]. - The company aims to enhance its competitiveness and market penetration by improving R&D efficiency, expanding into new business areas, and optimizing operations [2]. Group 2: Financial Data - The company reported a net loss of RMB 10,515.07 million for the first half of 2025, primarily due to low order prices and the early production stage of its projects [21]. - The company has fully utilized the raised funds for planned investments, with no reported issues in fund management or usage [10][20]. Group 3: Shareholder Information - The company has not disclosed any special arrangements regarding corporate governance or significant changes in major shareholders [3][4]. Group 4: Upcoming Events - The company will hold a performance briefing on August 27, 2025, to discuss its half-year results and address investor questions [5][8].